Opaleye Management Inc. - 26 Jul 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role: 10%+ Owner
Signature: Opaleye Management Inc., By: /s/ James Silverman, President
Issuer symbol: N/A
Transactions as of: 26 Jul 2022
Net transactions value: +$3,877
Form type: 4
Filing time: 26 Jul 2022, 17:25:58 UTC
Previous filing: 22 Jul 2022
Next filing: 12 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCON	Common Stock, par value $0.001 per share	Purchase	$3,877	+2,254	+0.61%	$1.72	370,000	26 Jul 2022	By Managed Account.	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TCON	Prefunded Warrants						1,889,513	26 Jul 2022	Common Stock	1,889,513	$0.0100	By Opaleye,L.P.	F2, F3
holding	TCON	Prefunded Warrants						1,358,593	26 Jul 2022	Common Stock	1,358,593	$0.0100	By Opaleye,L.P.	F2, F3
holding	TCON	Prefunded Warrants						2,205,018	26 Jul 2022	Common Stock	2,205,018	$0.0100	By Opaleye, L.P.	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F2	Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F3	The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.